1. Scrip
  2. >>Focus On Asia

HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US

 
• By Dexter Jie Yan

Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.

Asia strategy
HUTCHMED seeks partnerships to advance three molecules into the clinic outside of China. • Source: Shutterstock

Aiming to become profitable in 2025, HUTCHMED (China) Limited is likely to move away from running costly late-stage international clinical trials by itself, primarily in the US, and is instead seeking partnerships to advance three molecules into the clinic outside of China, company executives said during the group's R&D Day on 9 July.

Key Takeaways

  • HUTCHMED has initiated China-only Phase III or II/III clinical trials with three molecules, namely IDH 1 and IDH 2 dual inhibitor HMPL-306, Syk inhibitor sovleplenib and VEGFR/FGFR inhibitor surufatinib.

The new approach is mostly pronounced in the clinical development of its isocitrate dehydrogenase (IDH) 1 and IDH 2 dual...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.